FDA grants Priority Review for Lucentis in diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Endocrinology | Food and Drug Administration (FDA) | Grants | Lucentis | Pharmaceuticals | Ranibizumab Injection